<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="publisher-id">MEDI</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27749533</article-id><article-id pub-id-type="pmc">5059035</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000004810</article-id><article-id pub-id-type="art-access-id">04810</article-id><article-categories><subj-group subj-group-type="heading"><subject>3400</subject></subj-group><subj-group><subject>Research Article</subject><subject>Meta-Analysis of Observational Studies in Epidemiology</subject></subj-group></article-categories><title-group><article-title>Parathyroid hormone and risk of heart failure in the general population</article-title><subtitle>A meta-analysis of prospective studies</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Fanbo</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Wei</given-names></name><degrees>MM</degrees><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Jianghong</given-names></name><degrees>MM</degrees><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Baisong</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref><sup>&#x02217;</sup></xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Gilardi.</surname><given-names>Leonardo</given-names></name></contrib></contrib-group><aff id="aff1"><label>a</label>Department of Cardiology</aff><aff id="aff2"><label>b</label>Department of Cardiac Surgery, China-Japan Union hospital of Jilin University, Changchun, China.</aff><author-notes id="cor1"><corresp><label>&#x02217;</label>Correspondence: Prof. Baisong Lin, Department of Cardiology, China-Japan Union hospital of Jilin University, No. 126 Xiantai Street, Changchun 130033, China (e-mail: <email>lin_baisong@yeah.net</email>).</corresp></author-notes><pub-date pub-type="collection"><month>10</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>07</day><month>10</month><year>2016</year></pub-date><volume>95</volume><issue>40</issue><elocation-id>e4810</elocation-id><history><date date-type="received"><day>28</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>16</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">http://creativecommons.org/licenses/by-nc-nd/4.0</ext-link></license-p></license></permissions><self-uri xlink:type="simple" xlink:href="medi-95-e4810.pdf"/><abstract><title>Abstract</title><p>Inconsistent findings have been reported on the association between the parathyroid hormone (PTH) level and risk of heart failure. We aimed to systematically evaluate the association between circulating level of PTH and risk of heart failure in the general population by conducting a meta-analysis. We made a comprehensive literature search in PubMed, Embase, VIP, CNKI, and Wanfang databases published until January 2016. Only prospective observational studies reporting the association between circulating level of PTH and risk of heart failure in the general population were selected. Pooled adjusted hazard ratio (HR) and corresponding 95% confidence intervals (CIs) were calculated for the highest versus lowest PTH category. Six studies with 25,207 participants identified. Higher circulating level of PTH was associated with an increased risk of heart failure (HR: 1.38; 95% CI 1.09&#x02013;1.74) in a random effect model. Subgroup analyses revealed that the risk of heart failure was more pronounced among men (HR: 1.75; 95% CI 1.38&#x02013;2.22) than in both genders. However, the risk increment was not statistically significant (HR: 1.12; 95% CI 0.76&#x02013;1.66) in the middle-aged population. Higher PTH level is independently associated with an exacerbated risk of heart failure in the general population.</p></abstract><kwd-group><title>Keywords</title><kwd>heart failure</kwd><kwd>meta-analysis</kwd><kwd>parathyroid hormone</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec><label>1</label><title>Introduction</title><p>Heart failure is a globally public health concern, associated with considerable morbidity and mortality.<sup>[<xref rid="R1" ref-type="bibr">1</xref>]</sup> An estimated 5.7 million Americans have heart failure according to the data from NHANES 2009 to 2012,<sup>[<xref rid="R2" ref-type="bibr">2</xref>]</sup> and will afflict more than 8 million patients by 2030.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> Heart failure affects approximately 4 million people, with 550,000 new cases diagnosed annually in China.<sup>[<xref rid="R4" ref-type="bibr">4</xref>]</sup> Many potential risk factors contribute to the development of heart failure. Modification of these risk factors may help to reduce the incidence of heart failure as well as decrease mortality in patients with established heart failure. Therefore, early identification of these modifiable risk factors remains crucial.</p><p>Parathyroid hormone (PTH) is secreted by the parathyroid glands that control calcium homeostasis. Excess of PTH may adversely affect cardiovascular health beyond the regulation of calcium and phosphate homeostasis.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> To date, many observational studies have examined the relationship between circulating level of PTH and subsequent risk of heart failure in the general population<sup>[<xref rid="R6" ref-type="bibr">6</xref>&#x02013;<xref rid="R12" ref-type="bibr">12</xref>]</sup> as well as adverse outcomes in patients with heart failure.<sup>[<xref rid="R13" ref-type="bibr">13</xref>&#x02013;<xref rid="R15" ref-type="bibr">15</xref>]</sup> However, this association was not observed in all the studies. These conflicting findings among the studies may partly explain by differences in study population, lack of standardization of PTH assays, follow-up duration, gender difference, or adjustment for confounders. A well-designed meta-analysis revealed that higher circulating level of PTH was associated with excessive risk of cardiovascular events.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup> Moreover, a more recently published meta-analysis only focused on the association between higher circulating level of PTH and cardiovascular or all-cause mortality risk.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup></p><p>No previous meta-analysis has examined the relationship between circulating level of PTH and subsequent risk of heart failure. Therefore, we conducted this meta-analysis of available prospective studies to investigate the association between circulating level of PTH and incident heart failure in the general population.</p></sec><sec><label>2</label><title>Materials and methods</title><sec><label>2.1</label><title>Literature search</title><p>We performed this meta-analysis based on the guideline of the Meta-Analysis of Observational Studies in Epidemiology.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup> The ethical approval was not necessary for this meta-analysis because this study was only adopted the study-level data but not individual patients data. Two authors (FBM and WW) independently searched for all eligible prospective observational studies in Pubmed, Embase, VIP, China National Knowledge Infrastructure, and Wanfang databases published until January 2016. We combined the following search items: &#x0201c;parathyroid hormone&#x0201d; OR &#x0201c;hyperparathyroidism&#x0201d; and &#x0201c;heart failure&#x0201d; or &#x0201c;cardiac failure&#x0201d; and &#x0201c;follow-up&#x0201d; or &#x0201c;prospective,&#x0201d; with no restriction of language. In addition, reference list of the included studies and reviews on this topic was manually scanned for additional possible studies. If the outcomes were not reported in the original study, we contacted the corresponding author by e-mail.</p></sec><sec><label>2.2</label><title>Study selection</title><p>Studies that satisfied the following inclusion criteria were eligible: prospective observational studies that enrolled general population; studies that investigated the relationship between baseline circulating level of PTH and subsequent heart failure risk; and studies that reported adjusted hazard ratio (HR) and its corresponding 95% confidence intervals (CIs) of heart failure incidence. Studies that were cross-sectional design, abstract, or review were excluded.</p></sec><sec><label>2.3</label><title>Data extraction and quality assessment</title><p>Two independent authors (FBM and WW) used a standardized form to extract the relevant data from the selected studies. Any discrepancies between 2 authors were settled through discussion. The extracted data included first author's surname, years of publication, study design, geographic location, sample size, proportion of male, age of population, method of PTH assay, category of PTH comparison, number of events, most fully adjusted HR and 95% CI, follow-up duration, and variables adjusted. Two independent authors (FBM and WW) evaluated the quality of the included studies in accordance with the Newcastle-Ottawa Scale<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup> that allowed a maximal score of 9 stars. Studies with a rating of 5 or more stars were regarded as moderate to good quality.</p></sec><sec><label>2.4</label><title>Statistical analyses</title><p>Analyses were conducted using the STATA 12.0 software package (STATA Corp LP, College Station, TX). Pooled risk estimates were expressed as the HR with 95% CI for the highest versus lowest PTH category. The likelihood of statistical heterogeneity across studies was assessed by Cochrane <italic>Q</italic> test with significance set at 0.10 or less and <italic>I</italic><sup>2</sup> statistic more than 50%. We selected the random effects model when pooled analysis resulted in significant heterogeneity; otherwise, a fixed-effect model was applied. We applied both Begg test<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup> and Egger test<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup> to explore potential publication bias. Subgroup analyses were performed according to the sample sizes (&#x0003e;1000 vs &#x0003c;1000), duration of follow-up (median or mean &#x02265;10 years vs &#x0003c; 10 years), gender (male vs both gender), and age of patients (middle-aged vs older adults).</p></sec></sec><sec><label>3</label><title>Results</title><sec><label>3.1</label><title>Characteristics of the included studies</title><p>The detailed description of literature search and study selection process is shown in Figure <xref ref-type="fig" rid="F1">1</xref>. Six prospective studies<sup>[<xref rid="R6" ref-type="bibr">6</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>]</sup> were retrieved from 334 citations. The included studies were published between 2010 and 2014. Three studies were from the United States,<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>]</sup> 1 from Germany,<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup> 1 from Sweden,<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> and 1 from the United Kingdom.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> The sample size ranged from 864 to 10,392. The age of participants was over 35 years. Four studies<sup>[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref>&#x02013;<xref rid="R11" ref-type="bibr">11</xref>]</sup> included both men and women and 2 studies<sup>[<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R8" ref-type="bibr">8</xref>]</sup> enrolled only men. The follow-up duration ranged from 8.2 to 19 years. All the included studies are adjusted for the estimated glomerular filtration rate and common cardiovascular risk factors. Newcastle-Ottawa Scale stars ranged from 5 to 8 and overall methodological quality of included studies was moderate to good. Characteristics of the included studies are summarized in Table <xref ref-type="table" rid="T1">1</xref>.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Flow diagram of the study selection.</p></caption><graphic xlink:href="medi-95-e4810-g001"/></fig><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of the included studies.</p></caption><graphic xlink:href="medi-95-e4810-g002"/></table-wrap></sec><sec><label>3.2</label><title>Meta-analysis of incident heart failure</title><p>Relationship between circulating level of PTH and incident heart failure was reported in six studies. A total of 25,207 participants and 2561 heart failure events were analyzed. As shown in Figure <xref ref-type="fig" rid="F2">2</xref>, statistical heterogeneity (<italic>I</italic><sup>2</sup>&#x0200a;=&#x0200a;70.2%; <italic>P</italic>&#x0200a;=&#x0200a;0.005) was observed across six studies. Meta-analysis with a random effects model showed that higher circulating level of PTH was associated with an increased risk of heart failure (HR: 1.38; 95% CI 1.09&#x02013;1.74). Furthermore, pooled HR for heart failure was 1.27 (95% CI 1.14&#x02013;1.42) in a fixed-effect model. Begg test (<italic>P</italic>&#x0200a;=&#x0200a;0.452) and Egger test (<italic>P</italic>&#x0200a;=&#x0200a;0.203) did not provide evidence of substantial publication bias.</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Hazard ratio and 95% confidence intervals of higher circulating level of parathyroid hormone and risk of heart failure in a random effect model.</p></caption><graphic xlink:href="medi-95-e4810-g003"/></fig></sec><sec><label>3.3</label><title>Subgroup analyses and sensitivity analyses</title><p>In the subgroup analyses (Table <xref ref-type="table" rid="T2">2</xref>), the associations between higher circulating level of PTH and excessive risk of heart failure were not observed in the middle-aged persons (HR: 1.01; 95% CI 0.85&#x02013;1.21), and over 10 years follow-up (HR: 1.28; 95% CI 0.95&#x02013;1.71). Moreover, the risk of heart failure seemed more pronounced among men (HR: 1.75; 95% CI 1.38&#x02013;2.22). The results of the sensitivity analyses showed only minimal changes in magnitude and direction of the pooled HR when anyone study was excluded from the meta-analysis, suggesting the robustness of our findings (data not shown).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Subgroup analyses of parathyroid hormone and risk of heart failure.</p></caption><graphic xlink:href="medi-95-e4810-g004"/></table-wrap></sec></sec><sec><label>4</label><title>Discussion</title><p>This meta-analysis suggests that higher circulating PTH is associated with an excessive risk of heart failure in the general population. Participants with increased circulating PTH had a 38% excessive risk of heart failure in the overall patients and 75% excessive risk of heart failure among men.</p><p>In the stratified analysis, gender of patients modified the magnitude of heart failure risk. Men with higher PTH were associated with 75% excessive risk of heart failure than the both gender groups. This finding implies that higher PTH levels appeared to have a pronounced impact on men. Given there are significant differences in etiology of heart failure,<sup>[<xref rid="R22" ref-type="bibr">22</xref>]</sup> women as a subgroup for statistical analysis is warranted in the future study. However, the exact mechanisms for the observed differences remain unclear. In addition, the magnitude risk estimate was reduced in studies with more than 10 year's follow-up, suggesting heart failure events mainly occurred in the early follow-up duration. Furthermore, subgroup analysis indicated that the effect of PTH on incident heart failure was not statistically significant in middle-aged population. Age of participants appeared to modify the relationship between PTH and risk of heart failure.</p><p>The role of PTH as a potential risk factor for heart failure has been widely investigated.<sup>[<xref rid="R23" ref-type="bibr">23</xref>]</sup> Several studies did not include in this meta-analysis also investigated the relationship between higher circulating PTH and heart failure. Consistent with the finding of our study, subjects with higher baseline PTH value had a 43% greater risk of heart failure in a cross-sectional study.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> Higher PTH level was an independent risk factor for hospitalization<sup>[<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref>]</sup> in heart failure patients. Moreover, higher PTH level was also associated with 90% excessive risk all-cause mortality in heart failure outpatients.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> These findings suggest that circulating level of PTH predicts subsequent risk of heart failure in the general population as well as adverse outcomes in patients with heart failure. Possible mechanisms can explain the relationship between PTH and heart failure risk. Higher PTH promotes endothelial dysfunction<sup>[<xref rid="R24" ref-type="bibr">24</xref>]</sup> and increase aortic stiffness.<sup>[<xref rid="R25" ref-type="bibr">25</xref>]</sup> In addition, PTH is also linked to arterial hypertension<sup>[<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>]</sup> and left ventricular hypertrophy.<sup>[<xref rid="R28" ref-type="bibr">28</xref>]</sup></p><p>Several potential limitations should be acknowledged. First, substantial heterogeneity (<italic>I</italic><sup>2</sup>&#x0200a;=&#x0200a;70.2%; <italic>P</italic>&#x0200a;=&#x0200a;0.005) might reduce the reliability of our results. The differences in age, gender, sample size, follow-up duration, and severity of heart failure may be the sources of heterogeneity. Second, all the included studies enrolled the middle to older participants; therefore, our findings may not be generalized to younger population and women. Third, lack of repeated measurements of PTH level is a major limitation. A single baseline measurement may might have led to misclassification of participants or not accurately reflect the changes of PTH over time. Finally, included studies failed to adjust confounders in a consistent way. The lack of adjustment for phosphate, fibroblast growth factor-23 may have resulted in a slight overestimation of the risk estimate.</p></sec><sec><label>5</label><title>Conclusions</title><p>This meta-analysis indicates that increased PTH level is independently associated with an increased risk of heart failure in the general population. This risk seems more pronounced among elderly men. However, well-designed randomized controlled trial should be carried out to evaluate whether reducing the levels of PTH will decrease heart failure risk or attenuate the disease progression.</p></sec></body><back><fn-group><fn fn-type="abbr"><p>Abbreviations: CI&#x0200a;=&#x0200a;confidence interval, HR&#x0200a;=&#x0200a;hazard ratio, NOS&#x0200a;=&#x0200a;Newcastle-Ottawa Scale, PTH&#x0200a;=&#x0200a;parathyroid hormone.</p></fn><fn fn-type="COI-statement"><p>The authors have no conflict of interests to declare.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roger</surname><given-names>VL</given-names></name><name><surname>Weston</surname><given-names>SA</given-names></name><name><surname>Redfield</surname><given-names>MM</given-names></name><etal/></person-group>
<article-title>Trends in heart failure incidence and survival in a community-based population</article-title>. <source><italic>JAMA</italic></source>
<year>2004</year>; <volume>292</volume>:<fpage>344</fpage>&#x02013;<lpage>350</lpage>.<pub-id pub-id-type="pmid">15265849</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Go</surname><given-names>AS</given-names></name><etal/></person-group>
<article-title>Heart disease and stroke statistics---2015 update: a report from the American Heart Association</article-title>. <source><italic>Circulation</italic></source>
<year>2015</year>; <volume>131</volume>:<fpage>e29</fpage>&#x02013;<lpage>322</lpage>.<pub-id pub-id-type="pmid">25520374</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidenreich</surname><given-names>PA</given-names></name><name><surname>Albert</surname><given-names>NM</given-names></name><name><surname>Allen</surname><given-names>LA</given-names></name><etal/></person-group>
<article-title>Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association</article-title>. <source><italic>Circ Heart Fail</italic></source>
<year>2013</year>; <volume>6</volume>:<fpage>606</fpage>&#x02013;<lpage>619</lpage>.<pub-id pub-id-type="pmid">23616602</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>SS</given-names></name><name><surname>Kong</surname><given-names>LZ</given-names></name><name><surname>Gao</surname><given-names>RL</given-names></name><etal/></person-group>
<article-title>Outline of the report on cardiovascular disease in China, 2010</article-title>. <source><italic>Biomed Environ Sci</italic></source>
<year>2012</year>; <volume>25</volume>:<fpage>251</fpage>&#x02013;<lpage>256</lpage>.<pub-id pub-id-type="pmid">22840574</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomaschitz</surname><given-names>A</given-names></name><name><surname>Ritz</surname><given-names>E</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease</article-title>. <source><italic>Metabolism</italic></source>
<year>2014</year>; <volume>63</volume>:<fpage>20</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">24095631</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagstrom</surname><given-names>E</given-names></name><name><surname>Ingelsson</surname><given-names>E</given-names></name><name><surname>Sundstrom</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Plasma parathyroid hormone and risk of congestive heart failure in the community</article-title>. <source><italic>Eur J Heart Fail</italic></source>
<year>2010</year>; <volume>12</volume>:<fpage>1186</fpage>&#x02013;<lpage>1192</lpage>.<pub-id pub-id-type="pmid">20797986</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kestenbaum</surname><given-names>B</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>de Boer</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Vitamin D, parathyroid hormone, and cardiovascular events among older adults</article-title>. <source><italic>J Am Coll Cardiol</italic></source>
<year>2011</year>; <volume>58</volume>:<fpage>1433</fpage>&#x02013;<lpage>1441</lpage>.<pub-id pub-id-type="pmid">21939825</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wannamethee</surname><given-names>SG</given-names></name><name><surname>Welsh</surname><given-names>P</given-names></name><name><surname>Papacosta</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>Elevated parathyroid hormone, but not vitamin D deficiency, is associated with increased risk of heart failure in older men with and without cardiovascular disease</article-title>. <source><italic>Circ Heart Fail</italic></source>
<year>2014</year>; <volume>7</volume>:<fpage>732</fpage>&#x02013;<lpage>739</lpage>.<pub-id pub-id-type="pmid">25104043</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>di Giuseppe</surname><given-names>R</given-names></name><name><surname>Buijsse</surname><given-names>B</given-names></name><name><surname>Hirche</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study</article-title>. <source><italic>J Clin Endocrinol Metab</italic></source>
<year>2014</year>; <volume>99</volume>:<fpage>947</fpage>&#x02013;<lpage>955</lpage>.<pub-id pub-id-type="pmid">24423292</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bansal</surname><given-names>N</given-names></name><name><surname>Zelnick</surname><given-names>L</given-names></name><name><surname>Robinson-Cohen</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Serum parathyroid hormone and 25-hydroxyvitamin D concentrations and risk of incident heart failure: the Multi-Ethnic Study of Atherosclerosis</article-title>. <source><italic>J Am Heart Assoc</italic></source>
<year>2014</year>; <volume>3</volume>:<fpage>e001278</fpage>.<pub-id pub-id-type="pmid">25468653</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folsom</surname><given-names>AR</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Misialek</surname><given-names>JR</given-names></name><etal/></person-group>
<article-title>Parathyroid hormone concentration and risk of cardiovascular diseases: the Atherosclerosis Risk in Communities (ARIC) study</article-title>. <source><italic>Am Heart J</italic></source>
<year>2014</year>; <volume>168</volume>:<fpage>296</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">25173540</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>HL</given-names></name><etal/></person-group>
<article-title>Vitamin d, parathyroid hormone, and heart failure in a chinese elderly population</article-title>. <source><italic>Endocr Pract</italic></source>
<year>2015</year>; <volume>21</volume>:<fpage>30</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">25100378</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schierbeck</surname><given-names>LL</given-names></name><name><surname>Jensen</surname><given-names>TS</given-names></name><name><surname>Bang</surname><given-names>U</given-names></name><etal/></person-group>
<article-title>Parathyroid hormone and vitamin D--markers for cardiovascular and all cause mortality in heart failure</article-title>. <source><italic>Eur J Heart Fail</italic></source>
<year>2011</year>; <volume>13</volume>:<fpage>626</fpage>&#x02013;<lpage>632</lpage>.<pub-id pub-id-type="pmid">21415099</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>T</given-names></name><name><surname>Tanigawa</surname><given-names>T</given-names></name><name><surname>Onishi</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Serum intact parathyroid hormone levels predict hospitalisation for heart failure</article-title>. <source><italic>Heart</italic></source>
<year>2009</year>; <volume>95</volume>:<fpage>395</fpage>&#x02013;<lpage>398</lpage>.<pub-id pub-id-type="pmid">19001003</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>GY</given-names></name><name><surname>Zong</surname><given-names>GJ</given-names></name><name><surname>Chen</surname><given-names>JK</given-names></name><etal/></person-group>
<article-title>Serum parathyroid hormone levels predict hospitalization in outpatients of heart failure: a preliminary study</article-title>. <source><italic>Zhonghua Yi Xue Za Zhi</italic></source>
<year>2013</year>; <volume>93</volume>:<fpage>2205</fpage>&#x02013;<lpage>2208</lpage>.<pub-id pub-id-type="pmid">24169329</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Ballegooijen</surname><given-names>AJ</given-names></name><name><surname>Reinders</surname><given-names>I</given-names></name><name><surname>Visser</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies</article-title>. <source><italic>Am Heart J</italic></source>
<year>2013</year>; <volume>165</volume>:<fpage>655</fpage>&#x02013;<lpage>664</lpage>.<comment>664 e651-655</comment>.<pub-id pub-id-type="pmid">23622902</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><etal/></person-group>
<article-title>Parathyroid hormone, cardiovascular and all-cause mortality: a meta-analysis</article-title>. <source><italic>Clin Chim Acta</italic></source>
<year>2016</year>; <volume>455</volume>:<fpage>154</fpage>&#x02013;<lpage>160</lpage>.<pub-id pub-id-type="pmid">26835752</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stroup</surname><given-names>DF</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Morton</surname><given-names>SC</given-names></name><etal/></person-group>
<article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group</article-title>. <source><italic>JAMA</italic></source>
<year>2000</year>; <volume>283</volume>:<fpage>2008</fpage>&#x02013;<lpage>2012</lpage>.<pub-id pub-id-type="pmid">10789670</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>G</given-names></name><name><surname>Shea</surname><given-names>B</given-names></name><name><surname>O&#x02019;Connell</surname><given-names>D</given-names></name><etal/></person-group>
<source>The Newcastle&#x02013;Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses</source>. <comment><ext-link ext-link-type="uri" xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link></comment>.</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Begg</surname><given-names>CB</given-names></name><name><surname>Mazumdar</surname><given-names>M</given-names></name></person-group>
<article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source><italic>Biometrics</italic></source>
<year>1994</year>; <volume>50</volume>:<fpage>1088</fpage>&#x02013;<lpage>1101</lpage>.<pub-id pub-id-type="pmid">7786990</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source><italic>BMJ</italic></source>
<year>1997</year>; <volume>315</volume>:<fpage>629</fpage>&#x02013;<lpage>634</lpage>.<pub-id pub-id-type="pmid">9310563</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>AL</given-names></name></person-group>
<article-title>Heart failure in women</article-title>. <source><italic>Curr Heart Fail Rep</italic></source>
<year>2015</year>; <volume>12</volume>:<fpage>187</fpage>&#x02013;<lpage>195</lpage>.<pub-id pub-id-type="pmid">25633565</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gruson</surname><given-names>D</given-names></name><name><surname>Buglioni</surname><given-names>A</given-names></name><name><surname>Burnett</surname><given-names>JC</given-names><suffix>Jr</suffix></name></person-group>
<article-title>PTH: potential role in management of heart failure</article-title>. <source><italic>Clin Chim Acta</italic></source>
<year>2014</year>; <volume>433</volume>:<fpage>290</fpage>&#x02013;<lpage>296</lpage>.<pub-id pub-id-type="pmid">24704306</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosworth</surname><given-names>C</given-names></name><name><surname>Sachs</surname><given-names>MC</given-names></name><name><surname>Duprez</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis</article-title>. <source><italic>Clin Endocrinol (Oxf)</italic></source>
<year>2013</year>; <volume>79</volume>:<fpage>429</fpage>&#x02013;<lpage>436</lpage>.<pub-id pub-id-type="pmid">23402353</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirro</surname><given-names>M</given-names></name><name><surname>Manfredelli</surname><given-names>MR</given-names></name><name><surname>Helou</surname><given-names>RS</given-names></name><etal/></person-group>
<article-title>Association of parathyroid hormone and 25-OH-vitamin D levels with arterial stiffness in postmenopausal women with vitamin D insufficiency</article-title>. <source><italic>J Atheroscler Thromb</italic></source>
<year>2012</year>; <volume>19</volume>:<fpage>924</fpage>&#x02013;<lpage>931</lpage>.<pub-id pub-id-type="pmid">22785083</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>EN</given-names></name><name><surname>Curhan</surname><given-names>GC</given-names></name><name><surname>Forman</surname><given-names>JP</given-names></name></person-group>
<article-title>Parathyroid hormone and the risk of incident hypertension</article-title>. <source><italic>J Hypertens</italic></source>
<year>2008</year>; <volume>26</volume>:<fpage>1390</fpage>&#x02013;<lpage>1394</lpage>.<pub-id pub-id-type="pmid">18551015</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Ballegooijen</surname><given-names>AJ</given-names></name><name><surname>Kestenbaum</surname><given-names>B</given-names></name><name><surname>Sachs</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Association of 25-hydroxyvitamin D and parathyroid hormone with incident hypertension: MESA (Multi-Ethnic Study of Atherosclerosis)</article-title>. <source><italic>J Am Coll Cardiol</italic></source>
<year>2014</year>; <volume>63</volume>:<fpage>1214</fpage>&#x02013;<lpage>1222</lpage>.<pub-id pub-id-type="pmid">24480627</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soares</surname><given-names>AA</given-names></name><name><surname>Freitas</surname><given-names>WM</given-names></name><name><surname>Japiassu</surname><given-names>AV</given-names></name><etal/></person-group>
<article-title>Enhanced parathyroid hormone levels are associated with left ventricle hypertrophy in very elderly men and women</article-title>. <source><italic>J Am Soc Hypertens</italic></source>
<year>2015</year>; <volume>9</volume>:<fpage>697</fpage>&#x02013;<lpage>704</lpage>.<pub-id pub-id-type="pmid">26276450</pub-id></mixed-citation></ref></ref-list></back></article>